Miura, Miki
Shimizu, Hirotaka
Saito, Daisuke
Miyoshi, Jun
Matsuura, Minoru
Kudo, Takahiro
Hirayama, Daisuke
Yoshida, Masashi
Arai, Katsuhiro
Iwama, Itaru
Nakase, Hiroshi
Shimizu, Toshiaki
Hisamatsu, Tadakazu http://orcid.org/0000-0002-1178-3536
Funding for this research was provided by:
the Japan Sciences Research Grant for Research on Intractable Diseases (Japanese Inflammatory Bowel Disease Research Group) affiliated with the Japan Ministry of Health, Labour and Welfare
Article History
Received: 31 May 2021
Accepted: 23 September 2021
First Online: 30 September 2021
Declarations
:
: Tadakazu Hisamatsu has performed joint research with Alfresa Pharma Co., Ltd. and EA Pharma Co., Ltd.; received grant support from Mitsubishi Tanabe Pharma Corporation, EA Pharma Co., Ltd., AbbVie GK, JIMRO Co., Ltd., Zeria Pharmaceutical Co., Ltd., Daiichi-Sankyo, Kyorin Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Takeda Pharmaceutical Co., Ltd., Pfizer Inc., and Mochida Pharmaceutical Co., Ltd.; and received consulting and lecture fees from Mitsubishi Tanabe Pharma Corporation, AbbVie GK, Celgene K.K., EA Pharma Co., Ltd., Kyorin Pharmaceutical Co. Ltd., JIMRO Co., Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Pfizer Inc. Jun Miyoshi received lecture fees from JIMRO Co. and Takeda Pharmaceutical Co., Ltd. Minoru Matsuura received commercial research funding from AbbVie GK, Mitsubishi Tanabe Pharma Corporation, EA Pharma Co., Ltd., Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., and JIMRO Co. and received lecture fees from Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, AbbVie GK, Takeda Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Viatris Inc., Sandoz K.K., JIMRO Co., Nippon Kayaku Co., Ltd., Kissei Pharmaceutical Co., Ltd., EA Pharma Co., Ltd., and Zeria Pharmaceutical Co., Ltd. Katsuhiro Arai received grant support from Nippon Kayaku Co., Ltd. and received consulting and lecture fees from Mitsubishi Tanabe Pharma Corporation, Janssen Pharmaceutical K.K., EA Pharma Co., Ltd., AbbVie GK, Zeria Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Takeda Pharmaceutical Co., Ltd., Alfresa Pharma Corporation, Eli Lilly Japan K.K., and Nobelpharma Co., Ltd. Hirotaka Shimizu received grant support from Nippon Kayaku Co., Ltd. Hiroshi Nakase received honoraria from Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical Co., Ltd., Janssen Pharmaceutical K.K., and Abbvie GK and commercial research funding from Hoya Group Pentax Medical, Boehringer Ingelheim GmbH, and Daticho-Sankyo Co., Ltd. Toshiaki Shimizu received research grants from Otsuka Pharmaceutical Co., Ltd., Japan Blood Products Organization, EA Pharma Co., Ltd., and Kissei Pharmaceutical Co., Ltd. Miki Miura, Daisuke Saito, Yoshida Masashi, Takahiro Kudo, Daisuke Hirayama, Masashi Yoshida, and Itaru Iwama have no conflicts of interest.